NDAORALTABLET
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
15
Data completeness
6/8 — Strong
XCOPRI (cenobamate) by SK Life Science is sodium channel antagonists [moa]. Approved for focal onset seizure, primary generalized epilepsy, partial seizure. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XCOPRI (cenobamate) is an oral tablet containing a sodium channel antagonist approved by the FDA in November 2019 for treating partial-onset seizures in adult patients. It represents a novel mechanism of action in the antiepileptic drug class, working through sodium channel inhibition to reduce abnormal neuronal firing. XCOPRI is currently in its peak lifecycle stage, indicating strong market establishment and clinical adoption. The drug fills an important niche in epilepsy management for patients who may have inadequate response to or intolerance of existing antiepileptic therapies.
$0.1BPart D
13.1 years to LOEMechanism of Action
Sodium Channel Antagonists
Worked on XCOPRI at SK Life Science? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.